THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

: Jackowski et al.

INVENTION

: Biopolymer Marker Indicative Of Disease State Having A Molecular Weight Of 1998 Daltons

SERIAL NUMBER

: 09/846,346

FILING DATE

: April 30, 2001

EXAMINER

: Gabel, Gailene

GROUP ART UNIT

: 1641

OUR FILE NO.

: 2132.013

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on

Mail Stop: Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

- I, George Jackowski, do hereby declare as follows:
- 1. I am one of the named inventors of the application entitled "Biopolymer Marker Indicative of Disease State Having A Molecular Weight of 1998 Daltons", having U.S. Application Serial No. 09/846,346, filed April 30, 2001.
- 2. In the Office Action mailed on August 24, 2004, claims 36-40, (as originally presented) were rejected under 35 U.S.C. 112, first paragraph because the claimed invention allegedly contains subject matter which was not described in the specification in such McHale & Slavin P.A. 2132.013 -Declaration 37 CFR 1.132 Page 1 of 3

a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims (as currently amended) have been limited to an isolated biopolymer marker having SEQ ID NO:1 (the 1998 dalton marker) useful in methods for determining the presence of the biopolymer marker. The method of the invention as recited in claim 36 involves confirming the presence of the isolated biopolymer marker having SEQ ID NO:1 in the patient sample wherein the presence of the biopolymer marker is indicative of a link to Type II diabetes.

- 3. The data provided in attached Appendix A was originally filed in Applicant's application no. 09/846,330, now Pub. No. U.S. 2002/0160420, both applications were filed on April 30, 2001. The data further clarifies the identification of SEQ ID NO: 1 in serum samples of patients being evidentiary of Type II diabetes sampled from patients suffering from a variety of disease states, see page All of Appendix A.
- 4. This declaration (including the attached Appendix A) is provided in order to show data obtained from a clinical trial involving over 500 patients suffering from a variety of disease states, see page 32 lines 9 to 15 of Pub. No. U.S. 2002/0160420. The patient specific samples and data are used to formulate a library of proteomic materials having characteristics identifiable with both normal and abnormal physiological conditions or predictive hallmarks thereof. The data on page All of Appendix A indicates the patients from which the isolated biopolymer marker MCHale & Slavin P.A. 2132.013 -Declaration 37 CFR 1.132 Page 2 of 3

consisting of SEQ ID NO:1 (the 1998 dalton marker) was confirmed are linked to Type II diabetes. This Appendix A does not represent results obtained from additional experimentation. This data was obtained in the original experiments performed at the time of the invention.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

May 19 2004

George Jackowski

\\Ms2\client files\2100-2199\2132 -Syn-X\2132_000013 - Marker 1998\Amendments\2132_013_132_appendix.wpd



	Sequence	G)DFLAEGGGVR/G)	G)DFLAEGGGVR/G)	(G)DFLAEGGGVR(G)	E)GDFLAEGGGVR(G)	E)GDFLAEGGGVR(G)	E)GDFLAEGGGVR(G)	(E)GDFI AFGGVR(G)	E)GDFLAEGGGVR(G)	D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAFGGGVR/G)	G)EGDFL AFGGGVR/G)	G)EGDFI AFGGGVR/G)	G)EGDFLAEGGGVR/G)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	SASLL(R)	(H)RIHWESASLL(R)	(H)KINWESASLL(K)	(H)NITIMESASLL(K)	(H)DIUMESASIL(R)	SASLL(K)	۔ار	(H)NIHWESASLL(R)	SASL(R)	(A)RIHWESASLL(R)	SASLL(R)	OAUL(X)
	Sec	(G)DFLAI	(G)DFLAI	(G)DFLA	(E)GDFLA	(E)GDFLA	(E)GDFLA	(E)GDFI A	(E)GDFLA	(D)PEVR	(D)PEVR	(D)PEVR	(D)PEVRI	(D)PEVRI	(D)PEVRI	(G)EGDFL/	(G)EGDFL/	(G)EGDFLA	(G)EGDFLA	(G)EGDFL	(G)EGDFL△	(G)EGDFLA	(G)EGDFLA	(G)EGDFI A	(G)EGDFLA	WHIR(H)	(H)RIHWE	(H)RIHWE	(H)RIHWESASLL	(H)RIHWE	מארוא(ה)	מאחוא(ה)	מארומ(וי)	מארוא(רו)	JONESMON!		ביאירומירו	E CONTRACTOR	(H)RIHWESASLL(R)	LIJANESASCL(K)
	Protein Name	Alpha Fibrinogen	Alpha Fibrinogen	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement Car	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f							
	MM	1020	1020	1020	1077	1077	1077	1077	1077	1097	1097	1097	1097	/801	7801	907	200	007	907	007	1206	1206	1206	1206	1206	1211	177	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	4244
	DISEASE	W	M	Wi	S	MI	IMI	M	W	lype II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Don't Call	Donal Egiluza	Ranal Failure	Donal Failure	Renal Failure	Donal Failure	Post Callure	Renai Failure	Renal failure	Renal failure	Kenal failure	IMI	W	W	M	M	M	MI	M	Ψ	Stroke-ICH					Stroke-ICH
9 Patient History	Σ				W	Acite	Non		Rectal bleed Asthma Nippw	MI NIODA	A.fib. Diabetes smoker HTN	NITT (DWOIL)	A.fib. Diabetes, smoker, HTN									Unstable andina homodializaia	Unstable andina homocalousis	Rapid attal file Delet La Control	SISVIBIDOMEN NAC AN IOU COLLEGE STATES	GE (dastroesophageal) reflux		MI, NIDDM							Acute CVA, Basal ganglia	HIN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA	HTN, ICH	Prior CVA, acute CVA (L MCA)	HIN, acute CVA (R subcortical
Jer Age	65			77	58	52	65	_	29	77	62	73	62		82	67	77	80	65	20	65	99	68	8	77	65	20	92	28	52	3			24	\$ 5	1,4	2 2	8 6	7 5	7/
Gender	_			L	Σ		Σ		L	Ĺ	Σ	Σ	Σ		Σ	ட	ட	Σ	Σ	ட	նւ	Σ	Σ	u.	u.	Σ	щ	ц.	≅ :	Σ	Ž			L	- ≥	2	2	2	Σ	Ā
Code #	SJ CON 07	HNS-SJ28	HNS-SJ33	SJ CON 06	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ28	SJ CON 05	SJ CON 06	TWH-039	184-988	TWH-039	184-988	SJ CON 01	SJ CON 05	SJ CON 06	SO NOO CS	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	S S S S S S S S S S S S S S S S S S S	S CON S	HNS-S.122	HNS-8,128	HNS-S.133	CU-15	CU-18	CD-19	CH-30	23	CC-37	56

	Sednence	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)KIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)		(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	12	(T)HRIHWESASLL(R)	ıΙΞ	(T)HRIHWESASLL(R)	(T)HRIHWESASLI (R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)									
Drotein Mamo	Protein Marile	Complement Car	Complement Cat	Complement Cat	Complement	Complement Car	Complement C31	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
WM	1211	1211	1211	1211	1211	1244	1244	17.	1211	1211	1211	1211	1211	1211	1771	17.1	12.11	1211	1211	1211	1211	1211	1348	1348	348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348
Disease	분	HZ.	SF	SF	Ę	H.C.		ב כ	± 1	F .	±5	÷ ;	Ŧ.	5 5	7 2	בובס ב	בן ני	ביים	F .	150	Ŧ .	Ė	M	IVII	IVI	M	M	M		IN.	M	MII Marko IOI	Stroke-ICH	STOKE-ICH STOKE-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH
Patient History	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DFAD	STATE 3	S BOATS	STACES	STOCKER	Acute MI. CTAGE 2	ם ا	STAGE 4	STAGE 3	STAGE		STOTA	STAGES	STAGES	STAGES			Hemodialysis	homodialysis	cick morning.						ICH, secondary to AVM	HO HO	Actife CVA Basal garalia	HTM ICH Habit thelms	TAN STATE OF THE PRINCE OF THE	CVA (R MCA) used tPA	CVA, trailster to VA	Proc CVV 2014 CH	HTN acute CVA (P. NICA)	HTN Diabetes acute CVA /D podate)	יייין ביפטיטטי, מסתים כאר (ה המוימימו)
er Age	61	65	29	75	77	65	29	67	79	G	43	45	29	99	51	2	29	76	51	62	20	77	65	20	65	28	52	65				69	44	5	99	22	47	9	32	72	67	
Gender		ш		<u>L</u>	L	ш	Σ	Σ	Σ	Σ	Σ	Σ	Σ	щ	Σ	Σ	Σ	Ŀ	Σ	Σ	Σ	u.	Σ	ட	ш	Σ	Σ	Σ				L	ш	ш	Σ	≥	2	Σ	Σ	Σ	L	
Code #	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	69-NO	CU-12	CU-15	CU-10	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38	

Sequence	(T)HRIHWESASI (D)	(T)HRIHWESASI (R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)		(T)HRIHWESASLL(R)	(T)HRIHWESASI L(R)	(T)HRIHWESASI (R)	(T)HRIHWESASLL(R)	(T)HRIHWESASI I (R)	(T)HRIHWESASLL(R)	(D)SESDFLAEGGGVR(G)	(D)SESDEI AEGGGVEV	(D)SESDEI AFGGGVP(G)	(D)SESDEL AEGGGVD(G)	(D)SESDEI AEGGEVAG)	(D)SESDEL AEGGG/(D)	100000000000000000000000000000000000000																						
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen												
MW	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1350	1350	1350	1350	1350	1350	1350	200	1350	330	1350	1350	1350	1350	1350	1350	1350	
Disease	Stroke-ICH	Stroke-ICH	Stroke-ICH	± 5	÷ .	H.	+	분	CH:	CHF	CHF	CFF	보이	H I	÷ 1	± 1	Ŧ .	± 1	Ŧ .	<u> </u>	בוים ל	Ŧ .	ביי	THO	Renai Failure	Kenal Failure	MI Ponol Eathur	Donal Callure	Aerial Fallure	Ranal Failure	Mi	Donot Epilius	Netial railule	Nit Cond	Renal Fallure	IM	Ž.	Ĭ	Ξ	Σ	Ψį	!
Patient History	HIN, Prior CVA, ICH (R thalamic hemorrhage)	HIN, PHOLOVA, CVA	STAGE 3	STAGE 3	STAGES	S TO TO	OTAGE 4	פשארוס	0 100 C	OTAGES - DEAD	STAGES	STAGES	STAGES			STAGE	STAGE 3		STAGE 3																							
Age 1	5 9	43	9	65	29	75	77	65	67	67	5/2	င့	43	45	59	99	51	2	59	9/	51	62	20	82	29	77	77	80	65	92	20	20	92	65	58	52	i i	+	+		1	
Sender M	2	Σ	Σ	ц	L.	<u>L</u>	u	L	Σ	Σ	≥	Σ	Σ	Σ	Σ	ட	Σ	Σ	Σ	ıL	Σ	Σ	Σ	Σ	L	ш	L	Σ	Σ	Σ	ц.	u.	ц	u.	Σ	Σ	Σ					-
# 8000 CII-60	011-66	CU-75	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105-FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 05.	SJ CON 06:	SJ CON 06:	STCON 08	SJ CON 07	SJ CON 07	SJ CON 10	SJ CON 10	1SJ CON 14	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-8,122	HNS-S.128	HNS-SJ33		

Continuo	Ballanhan	(D)SESUFLAEGGGVR(G)	(D)SESDE AEGGVA(G)	(B)DALKSEYALBEKIN	(D)DAUKOEVAUDEKID	(U) ATARASARA(V)	(A)DATASEVATIKI(D)	(N)DATASEVARKFK(D)	(R)DAHKSEVAHRFK(D)	(K)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(I)THRIHWESASLL(R)	(I)THRIHWESASL (R)	(I)THRIHWESASI (R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(i)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)						
Protein Name	Alnha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Serum Albumin	Serum Albumin	Serum Albumin	Senim Albumin	Senim Athimin	Section Albumin		Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C31	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f										
MW	1350	1350	1350	1406	1406	1406	1406	1406	1406	1406	1406	1400	400	004	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	440	2440	2777	1448	244	1463	1449	1449	1449	1449	1449	446	4440	1443
Disease	Renal failure	Renal failure	Renal failure	CHF	뜻	CHF	CFF	SFF	CAF	H.	HS.	PH.	100		INI	IMI	IMI	M	W.	W.	Σ	Œ.	×	W	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke ICH	Ottobal City	Stroke-10T	Stroke-101	Stroke-IOH	Stroko IOI	Citore-ion	Stoke-ICH	Stroke-ICH	Stroke-ICH Stroke-ICH	Stroke-ICH	Stroke-ICH	CUCACION	F	= 5
Patient History	Unstable angina, hemodialysis	Unstable angina, hemosdialysis	Rapid atrial Fib, Prior Hx CAN hemodialysis	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3		STAGE 3											LOT conception to	ion, secondary to AVIM	Acute CVA Baselia	HTN ICH dobt thalmic	HTN. acute CVA	HTN, ICH (cerebellar vermis)		CVA, transfer to VA	HTN, ICH	HAN ICH	Prior CVA acute CVA (1 MCA)	HTN acute CVA (Benconton	HTN Dishotes on the Control	HTN Prior CVA ICH (P thotamic bonners)	HTN Prior CVA CVA	HTN Prior CVA 10H		STAGE 3					
التا	99	88	2	5	8	8	51	9	29	76	51	62	20	77	65	20	65	28	55	65				90	34	54	99	20	76	72	47	55	56	72	72	67	+	┿	43	61	65	
Gender	≥ :	Σ		≦ :	≥	L:	Σ.	Σ	Σ	ıL	Σ	Σ	Σ	щ	Σ	ш	u	Σ	Σ	Σ				ш	. u	L	Σ	Σ	u.	Σ	Σ	Σ	Σ	Σ	Σ	u_	Σ	Σ	Σ	Σ	u.	
Code #	W CON OF	S CON 11	20000	23424 EBV	22042	22120 - CL	2340F FR	23 103 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	F.NS-S.133	69-NO	CU-12	CU-15	CU-10	CU-14	CU-16	CU-18	CU-19	CU-28	CU-30	CU-33	CU-37	CU-38	09-NO	SU-66	CU-75	23604 - KKB	23707 - KL	

	ezuenhec	ı	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASI (R)	(I)THRIHWESASI I (R)	(I)THRIHWESASI (B)	11.	(I)THRIHWESASI (B)	(I) THRIHWES AS I (D)	(I)THDIHWEGGE (D)	() THE INTERVELLA	(I) I TANDINING ASLL(R)	(I) TININVESASEL(R)	(I) THINKESASEL(R)	(I) I HKIHWESASLL(R)	(I) I HKIHWESASLL(R)	(I) I HEIHWESASLL(R)	(A)US(GEGUFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(D) DALIVE STATE (D)
Protein Name	Complement C34	Complement Cal	Complement CST	Complement C31	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Caf	Complement C3f	Complement Cat	Alaba Elbringgo	Alaha Citain	Alpha Fibringen	Alpha ribiliogen	Alpha Fibracian	Alpha ribiliogen	Alpha Fibricas	Alpha ribinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Serum Albumin	Serum Albumin	Serum Albumin	Senim Albumin				
MW	1449	1440	1440	7440	644	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1465	1465	1465	1165	1465	1465	1465	1465	1465	400	1400	2041	1465	1400	1400	1465	1518	1518	1518	1521	1521	1521	1521
Disease	CHF	SEC.	HE.	שכט	5 0	ביים	는 C	CHF	FRO.	농	SF	품	托	SFF	CFF	CHF	CHF	SFF	분	SFF	Renal Failure	Renal Fallure	Renal Failure	Robal failure	Repaired failure	Stroke-IOL	Stroke-IOH	Stroke DE	Stroke ICI	COLONG-10-10-10-10-10-10-10-10-10-10-10-10-10-	Stroke-ICH	Ψ.	W	<u> </u>	Kenal Fallure	Kenal Fallure	Renal Failure	Kenal Failure					
Pa	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 2	0 10010	S TO VEO	SUPPLO	S IN A STANCE		STAGE 3	SIAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3								Unstable angina, hemodialysis	Unstable angina, hemosdialvsis	Rapid atrial Fib, Prior Hx CAN hemodialveis	ICH	HTN, ICH right thalmic	HTN, ICH (cerebellar vermis)	HTN, acute CVA (R subcortical	HTN Diabetes acute CVA /D project	(In parietal)							
~ III	67	75	11	65	29	67	0,2	9	43	45	200	99	3 4	0 0	3 5	3 3	श्र	6	29	9	82	67	77	8	65	22	92	99	68	80	44	99	92	72	29	92	20		82	67	77	08	
Gender		ш.	L	L	Σ	Σ	Σ	Σ	Σ	Σ	Σ	L	- 2	2	≥ 2	٤		Σ :	∑:	≥ :	Σ	_	L	Σ	Σ	ц.	ഥ	Σ	Σ	ц.	ட	Σ	ட	Σ	u.	Σ	L		Σ	և	L	Σ	
# epo 2	22/03 - MMS	20205 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FR	22813 - CI	23130 - ER	23105 - EC	23446 FC	20110-110	23130 EB	22424	20104 - 10	20102 - EAB	10 CON 01	SO NO	SJ CON 06	90 NOO 78	ST CON 04	87408-10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	CU-12	CU-10	CU-16	CU-37	CU-38	SJ CON 07	SJ CON 10	HNS-SJ22	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 09	

Sections		(N)DATINGENATION (P)	(P)DAHKSEVAHKFKD(L)	(P)DAUXEVANATAUL)	(R)DAHKSEVAHKFKU(L)	(B)DAHKEVADBEKEK	(D)DNHEDDAGI DEIXX	(D) MITCHAGE ENT(-)	(D)PNHFRPAGLPEKY(-)	(T)ADSGEORI AFOCO (F.C.)	(K)ITHDIDIVERARI (C)	(K)THRIHWESASI (B)	(K)ITHRIHWEGAGI (D)	(K)ITHRIHWESASI I (R)	(K)ITHRIHWESASI I (B)		(K)ITHRIHWESASI I (R)	(K)ITHRIHWESASI I (R)	(K)ITHRIHWESASI (R)		11_	(K)ITHRIHWESASLL(R)		(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	١١.	(A) I HRIHWESASLL(R)	(K) THE PRINCES (R)	(K)ITHBIHMESASLL(K)	(K)THDINNESASEL(K)	(K)THRIHMESASI (B)	(K)ITHRIHWESASI (B)	(K)ITHRIHWESASI I (R)	(K)ITHRIHWESASI (R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)TUDIUM/COASI - /O
Protein Name	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Amyloid A	Serum Amyloid A	Serum Amyloid A	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Car	Complement Car	Complement C3f	Complement Caf	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
MW	1521	1521	1521	1521	1521	1521	1525	1525	1525	1536	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	7001	7961	7001	1582	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	7901	7001	7001
Uisease	Renal Failure	Renal Fallure	Renal Failure	Renal failure	Renal failure	Renal failure	≅	W	W	¥	Σ	Ž	ĮΣ.	Σ	Ĭ.	ž	2	IN IN	¥ .	ב	F 12		L 13	35	HS.	몱	동	CHF	CHE	托	SF	꿈	분	분	7 5	5 6		3	===
				I Instable and the Little of t	Rapid atrial Eth December	THE THE TANK OF THE CAN DEMOCIALLY SIS													STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	- {	Acute MI - STAGE 3	STAGES	STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	
65	200	99	99	89	8	တ္တ			1	77	65	20	92	28	52	92			61	. 65	29	75	77	92	67	20	6	3 5	र प्र	2 02	99	51	2	59	76	51	62	20	1
Σ	L	L	L	Σ	L	L				Ш	Σ	և	LL ,	Σ	Σ	Σ			Σ	ıL	L	u.	11.	L	≥ :	٤ ٤	≥ ≥	Σ	2	2	L	Σ	Σ	Σ	F	Σ	Σ	Σ	L
SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	SJ CON 10	HNS-SJ22	HNS-SJ28	HNS-SJ22	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ33	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	23000 OF	23408 - GFB	20208 - HIE	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	- 00 NO 7

ŧ.

	2	ď		Cladad	2012	Protein Name	
SJ CON 10	L	3 5		ĕ	1616	Complement	Sequence
S.I CON 14		8 8		¥	1616	Complement	
S.I CON 47	- =	S		W	1616	Complement Car	
OF NOO!	<u> </u>	S		W	1616	Complement Car	
S 100 00	≥ :	6		Į	100	Complement C3f	
200	≅	8		V	1010	Complement C3f	1
11/10 0 120		_		Σ	0 70	Complement C3f	
2760		_		17.4	010	Complement C3f	
HNS-SJ33				įΣ.	1616	Complement C3f	
SJ CON 06	և	77		W	1616	Complement C3f	
SJ CON 07	≥	92		Ψ	1690	Complement C3f	ימירים אינייומטדואיפי
SJ CON 10	u	20		Σ	1690	Complement C3f	(S)KITHDIMMESASEL(K)
SJ CON 14	u.	65		≅	1690	Complement C3f	(S)KITHOLIMINGS (S)
SJ CON 17	Σ	28	11.11.11.11.11.11.11.11.11.11.11.11.11.	₩	1690	Complement C3f	(S)VITUDII WITO CO. (T)
CO-69	L.	8	TOL COCCOCC	¥	1690	Complement C3f	(S) NITUDII INTEGRASIL (R)
CU-12	L.	44	Continue of the second of the	Stroke-ICH	1690	Complement C3f	(S)VITUDITIVE SASLL(K)
CU-15	u.	54		Stroke-ICH	1690	Complement C3f	(S) ATT THE WESASTE (R)
CU-10	Σ	99	DTN ON Basal ganglia	Stroke-ICH	1690	Complement C3f	(S)AITHRIHWESASLL(R)
CU-14	Σ	200	HTN CO.	Stroke-ICH	1690	Complement C3f	(S)KITHENESASLL(R)
CU-16	LL.	76	- 1	Stroke-ICH	1690	Complement C3f	(S)VITTERINGESASTE(R)
CU-18	Σ	73	HTN COLUMN COLUMN (CATEDONIA)	Stroke-ICH	1690	Complement C3f	(S)/ITINESAST (R)
CU-19	Σ	47	They previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1690	Complement C3f	(S)KITHKIHWESASLL(R)
CU-28	Σ	55	CVA, transfer to VA	Stroke-ICH	1690	Complement C3f	(S)/II HRIHWESASLL(R)
CU-30	Σ	38	I CH	Stroke-ICH	1690	Complement C3f	(S)NITHRIHWESASLL(R)
CU-33	2	3 5	HIN, ICH	Stroke-ICH	1690	Complement C3	
CU-37	2	7 5	LTN CVA, acute CVA (L MCA)	Stroke-ICH	1690	Complement Cat	(S)KITHRIHWESASLL(R)
CU-38	u	37	HIN, acute CVA (R subcortical	Stroke-ICH	1690	Complement Caf	(S)KITHRIHWESASLL(R)
CU-60	. 2	3 2	HIN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1690	Complement C3f	(S)KITHKIHWESASLL(R)
CU-66	Σ	40	UTNI DE CYA, ICH (R thalamic hemorrhage)	Stroke-ICH	1690	Complement C3f	(S)/ITITION (R)
CU-75	Σ	43	LTN PACON CVA	Stroke-ICH	1690	Complement C3f	(S)KITHBILWESASL(R)
23604 - KKB	Σ	2	STACH CAN ICH	Stroke-ICH	1690	Complement C3f	(S)KITURIUMESASLL(K)
23707 - KL	L.	8	01AGE 3	SAF	1690	Complement C3f	(S)KITHDILWINGS (K)
22703 - MMS	u.	67	S HOVE	농	1690	Complement C3f	(S)KITHDILIMITO SOLI (R)
20206 - MM	u	72	31,000.0	문	1690	Complement C3f	(C) WITH THE WESTER (K)
22103 - GM	·	12	STAGE 4	CHF	1690	Complement C3f	(S)VITHRIHWESASLL(R)
21813 GP	L	10	STAGE 3	분	1690	Complement	(S)KITHKIHWESASLL(R)
23008 - GEB	Ť	3 8	STAGE 3	당	1690	Complement O3	(S)KITHRIHWESASLL(R)
23402 - 01 5	+	ò	STAGE3 - DEAD	CHF	1600	Complement	(S)KITHRIHWESASLL(R)
Z L	+	6	STAGE 3	HZ.	1600	Complement C3f	(S)KITHRIHWESASLL(R)
71H - 00707	1	6/	STAGE 3	35	1690	Complement C3f	(S)KITHRIHWESASLL(R)
22803 - HB	1	8	STAGE 3	200	1090	Complement C3f	(S)KITHRIHWESASLL(R)
ş	Σ	43	STAGE 3	5 0	080	Complement C3f	(S)KITHRIHMECACI (C)

=

	Sequence	(S)KITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)		(S)SKITHKIHWESASLL(R)	(S)SKITHBILINGS (S)	(S)SKITUBIUMESASLL(R)	(S)SKITHRIHWESASIL (R)	(S)SKITHRIHWESASI (P)	(S)SKITHRIHWESASI I (B)	(S)SKITHRIHWESASI I (R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)		(S)SKITHBILIMESASLL(R)	(S)SKITHBIHWESASL(R)	(S)SKITHRIHWESASI (B)	(S)SKITHBIHWESASLL(R)	(S)SKITHRIHWESAST (R)	(S)SKITHDIUMESASLL(R)	(S)SKITHRIHWEGASI (B)	יייייייייייייייייייייייייייייייייייייי	(S)SKITERITWESASSIVE	(S)SKITHRIHWESASLL(R) (S)SKITHRIHWESASI I (R)									
Protein Name	r oten name	Complement C3f	Complement Car	Complement Car	Complement	Complement C31	Complement Car	Complement Car	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Car	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat	Complement Caf	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat		Complement C3f
MM	1000	1690	1690	1690	1890	1800	1690	1800	1600	1090	1777	1111	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	////	1///	1777	1777	1777	1777	1777	1777	1777	1777	1777		1777		
Disease	HEC.	H.S.	SH.	FS	HS.	H.C.	분	THO THO	H.	317	Tyne II Diahetes	Type II Diabetes	Type II Diahetes	Type II Diabetes	M	Type II Diabetes	Type II Diabetes	Type II Diabetes	M	WI	Σ	ĮΣ.	Stroke-ICH	Orionario Orionario	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	100	Stroke-ICH
	Acut		STAGE	STAGE							NIDDM, CHF, Hypothalemia??	patient died of CA Dec. 22/98		hemodialysis		MIDUM, HIN, Rio?? Angina		Apriasia, Kr nemiparalysis,				ICH. secondary to AVM	HO	Acute CVA, Basal ganglia	HTN, ICH right thalmic	HTN, acute CVA	HTN, ICH (cerebellar vermis)	HIN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA		N // NA	HTN acute CVA (P. MCA)	HTN Diabetes south OVA to	HTN PACE CVA (R parietal)	HTN Prior CVA CVA			STAGE 3
ᆚᆫ	5	29	8	0	8	29	9	6	62	2	82	82	67	;;	> 6	3 2	76	92	50	65	28	69	44	54	99	20	9 5	7,7	55	56	72	72	67	49	49	5	2	61
	∑ :	Σι	1	≥ :	≥ :	Σ	1	≅ :	∑ ;	Σ.	∑ :	Σ	L	٠ ١	2	Σ	Σ	Σ	ш	ıL	Σ	ч	ıL	ч	∑:	اح	- ≥	Σ	Σ	Σ	Σ	Σ	L	Σ	Σ	2		Σ
20803 - EW	V 2 - EVOUS	23421 - FB	23130 - CL	2310F FC	23116 50	20110-10	23430 EB	22130 - ER	20104 - PC	0102 - EAB	SON OF	SO CON DI	30 CON 05	90 NOO 18	SJ CON 09	TWH-002	TWH -009	SJ CON 07	SJ CON 10	SJ CON 14	J CON 17	CO-69	CU-12	CU-15	CU-19	4 4	CE-19	CU-19	CU-28	CU-30	CU-33	CU-37	CU-38	CU-60	CU-66	CU-75	,	23604 - KKB

:

Hx of prostate CA, hemodialy Complete hemianopia, smok Stroke, PM Hx, NIDDM, incr	

Gender Age Patient History M 52 M 65	<u>}</u>		Disease MI	MW 1865	Protein Name	Sequence
+			Ξ	1865	Complement C34	(+)SSKITHRIHWESASLL(R)
			Σ	1865	Complement Caf	
			Σ	1865	Complement C3f	(+)SSKITUBILIMESASLL(R)
69 ICH. secondary to AVM	_		₹	1865	Complement C3f	(+)SSKITHRIHWEGASIL(R)
HOI		בול מו	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
Acute CVA, Basal ganglia	a	j v	Stroke-10H	1900	Complement C3f	(+)SSKITHRIHWESASLL(R)
HTN, ICH right thalmic		o o	Stroke-IOH	000	Complement C3f	(+)SSKITHRIHWESASLL(R)
HTN, acute CVA		100	Stroke-ICH	1900	Complement C3f	(+)SSKITHRIHWESASLL(R)
HTN, ICH (cerebellar vermis)	(S)	Str	Stroke-ICH	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
HTN, previous CVA, CVA (R MCA) used tPA	ed tPA	Stro	Stroke-ICH	1865	Complement Car	(+)SSKITHRIHWESASLL(R)
o VA:		Stro	Stroke-ICH	1865	Complement C3f	
HIN, ICH	Stro	Stro	Stroke-ICH	1865	Complement Caf	(+)SSKITHRIHWESASLL(R)
Proc CVA Series CVA		Stro	Stroke-ICH	1865	Complement C3f	(+)SSKITUBIUMESASLL(R)
HTN acute CVA (L MCA)	(V)	Stro	Stroke-ICH	1865	Complement C3f	(+)SSKITHBIHMESASIL (R)
HTN Disheles 2010 CA A	g	Strok	Stroke-ICH	1865	Complement C3f	(+)SSKITHDIHMESASLL(K)
HTN. Prior CVA ICH (R thalamle borner)	(all)	otro otro	Stroke-ICH	1865	Complement C3f	11
HTN. Prior CVA CVA	rmage)	STOK	E C	1865	Complement C3f	(+)SSKITHRIHWEGAGI (D)
HTN. Prior CVA ICH		STOR	5 5	1865	Complement C3f	(+)SSKITHRIHWESAS!!(R)
STAGE 3		5 0	5	1805	Complement C3f	(+)SSKITHRIHWESASLL(R)
STAGE 3	Ö		- 4	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
STAGE 3	5	ြင်		1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
77 STAGE 4 CI	ō	ਹ	붕	1865	Complement Cal	(+)SSKITHRIHWESASLL(R)
STAGE 3	ō	ō	CHF	1865	Complement C3f	(+)SOKITHRIHWESASLL(R)
STAGES STAGES	3	히	4	1865	Complement C3f	(+)SSKITHRIHWESASIL(K)
67 STAGE 3	5 6	5 6	<u> </u> <u> </u>	1865	Complement C3f	(+)SSKITHRIHWESASI (R)
STAGE 3	5 2	5 2	<u> </u>	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
STAGE 3	5 3	5 3	. u	1885	Complement C3f	(+)SSKITHRIHWESASLL(R)
STAGE 3		3		1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
Acute MI - STAGE 3	E3	3		1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
STAGE 3		5 2		1000	Complement C3f	(+)SSKITHRIHWESASLL(R)
		5 2		COSI	Complement C3f	11_
	5 6	5 6	L 1	1865	Complement C3f	(+)SSKITHRIHWESASI (A)
3	5 6	5 0	-	1865	Complement C3f	
3		3 0	7 1	1865	Complement C3f	(+)SSKITHRIHWESASI (R)
			날!	1865	Complement C3f	(+)SSKITHRIHWESASI (P)
STAGE 3			+10	1865	Complement C3f	(+)SSKITHRIHWESASI I (R)
3				202	Complement C3f	11_
			ב	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)

92		STAGE3	OLE	MW	Protein Name	Sequence
67	_	STAGE3 - DEAD	ב	2021	Complement C3f	(+)SSKITHRIHWESASI ! R(-)
67		STAGE 3	1.00	2021	Complement C3f	(+)SSKITHRIHWESASI I BL.
79		STAGE3	ב	2021	Complement C3f	(+)SSKITHRIHWESASI 1 R(-)
8		STAGE 3		2021	Complement C3f	(+)SSKITHRIHWESASI B(-)
8	m	STAGE 3	בין	2021	Complement C3f	(+)SSKITHRIHWESASI I R(-)
45	10	Acute MI - STAGE 3	ביין	2021	Complement C3f	(+)SSKITHRIHWESAS! R/-)
8	6		F	2021	Complement C3f	(+)SSKITHBIHMES(+)
9	99	STACE A	는 건	2021	Complement C3f	- VASKITEDIOWEGOVII DI
51	-	STAGE 3	동	2021	Complement C3f	(+)SOKITUDITIVES (+)
9	97	SHOCK	CHE	2021	Complement C3f	(+)SOMITING WESTER(-)
ν.	20	01AGE 3	불	2021	Complement C3f	(+)SSKITHRIMWESASLLR(-)
1	3 4	STAGE 3	CHF	2021	Complement C3f	(+)SONITHERMESASTER(-)
2	1	SIAGE 3	CHF	2021	Complement Cafe	(+)SSKI HKIHWESASLLR(-)
5 6	- 6	STAGE 3	CH	2021	Complement	(+)SSKITHRIHWESASLLR(-)
3 5	1	STAGE 3	CHF	2021	Complement	(+)SSKITHRIHWESASLLR(-)
1	+	STAGE 3	품	2021	Complement Cor	(+)SSKITHRIHWESASLLR(-)
	+		Type II Diabetes	2021	Complement Car	(+)SSKITHRIHWESASLLR(-)
[+		Tybe II Diabetes	2024	Complement C31	(+)SSKITHRIHWESASLLR(-)
	1		Type II Diahetes	2024	Complement CST	(+)SSKITHRIHWESASLLR(-)
- [+		Type II Diahetes	2024	Complement C3f	(+)SSKITHRIHWESASLLR(-)
	+		Tyne II Dishotos	7000	Complement C3f	(+)SSKITHRIHWESASLLR(-)
- 1	+		Tyne II Diabates	7000	Complement C3f	(+)SSKITHRIHWESASLLR(-)
6	-	STAGE 3	OHE CHOOLES	1707	Complement C3f	(+)SSKITHRIHWESASLLR(-)
8	9	STAGE 3	3	2000	Complement C3f	SSKITHRIHWESASLLR
	/9	STAGE 3	E	2000	Complement C3f	SSKITHRIHWESASLLR
\sim	75	STAGE 4	THE CONTRACT OF THE CONTRACT O	2000	Complement C3f	SSKITHRIHWESASLLR
1		STAGE 3	בוכ	2000	Complement C3f	SSKITHRIHWESASLLR
8	2		1100	8007	Complement C3f	SSKITHRIHWESASI I B
67	7		5 6	2056	Complement C3f	SSKITHRIHWEGAGILD
67	7	STAGE 3	5 6	2056	Complement C3f	SSKITHRIHWEGAGI I D
79	0	STAGE 3	5 6	2056	Complement C3f	SSKITHRIHWEGAGI - D
8		STAGE 2	F	7026	Complement C3f	SSKITHRIHWEGASI I D
43	_	STAGE 3	3	2056	Complement C3f	SSKITHRIHWEGAGILD
3	1.0	ļ	Ŧ	2056	Complement C3f	SSKITHDHAMEONOLD
29		וכ	붕	2056	Complement C3f	SCKITUDIUMEDAGLER
18	+	01700	CHF	2056	Complement C3f	SOKITIBILITIES
3 2	Ŧ	SIAGE 4	CHF	2056	Complement Caf	SOLITHRIHWESASLLR
2 2	4	STAGE 3	CHF	2056	Complement	SSKIIHRIHWESASLLR
8 2	+	STAGE 3	분	2056	Complement Car	SSKITHRIHWESASLLR
20	4	STAGE 3	E	2056	Complement C3f	SSKITHRIHWESASLLR
2	_	STAGE 3		2007	Complement C3f	SSKITHRIHWESASLLR
5		STAGE 3		0007	Complement C3f	SSKITHRIHWESASI I B
۱						

		Sequence		SONI DRIDWESASILR	SSKITHRIHWESASI - B	(A)TVGSI AGODI OEDA OMOGRA	WITH SOUTH CENTRAL AWGERL(R)	(A) I VOSLAGGELCERACIAMOERL(R)	(A)TVGSLAGQPLQERADAWGFRI (R)	(R)DAHKSEVAHREKDI GEENIEKALVI (V. IV.	(B)DAHKSEVALDEKDI OFFICE	(I) JANUERENIKALALI	(K)DAHKSEVAHRFKDLGEENFKAI VI /IV	(R)DAHKSFVAHREKDI GEENEVALVI	/P/OALKOCYALIOFIXE OFFICE	(I) TATELY ATTRIBUTE TO THE CONTROL (I)	(R)DAHKSEVAHRFKDLGEENFKAI VI 14/F)	(R)DAHKSEVAHREKDI GEENEKALVILAGE	(R)DAHKSEVALDEKDI OFFICE (CALIFICAL)	(*)COMMON AND LONG ENTRAL VLIA(F)	(R)DAHKSEVAHRFKDLGEENFKALVI IA/F)	(R)DAHKSEVAHREKDI GEENEKAI VI 10/E	(ש) עודי אדעי וגיודיטייטיי
	Protein Name	i otali Nalije	Complement C3f	Social Second	Complement C31	Apoliprotein E	Apoliprotein F	Annilar A	Apoliprotein E	Serum Albumin	Serum Albumin	Somm Albumia		Serum Albumin	Serum Albumin	O O THE ALL	Seigni Albumin	Serum Albumin	Serum Albumin	Son Marie	Service Albumin	Serum Albumin	
	MΜ		2056	2056	┸	72267	2267	2267	_Ł	- 1	2753	2753	L	2/23	2753	2037	1	_1	2937	2937	- [4937	
	Disease	11.00	F.	岩	in October	HISONIA RESISTANCE	Insulin Resistance	Insulin Resistance	Denlin Dogloto	Tradill Pesisiance	Insulin Resistance	Insulin Resistance	Inequilio Decistori	HISCHILL RESISTANCE	Insulin Resistance	Insulin Resistance	Joen lin Dogiota	Postilia Casistance	IIIsulin Resistance	Insulin Resistance	Institin Posistance	an in colored in color	
Patient Lieten	y augut mistory	STAGE 3	O LO VEO	SIAGES	Insulin Resistance	Institle Besistance	בייוויים בייווים ביי	IIISUIIII Kesistance	Insulin Resistance	Insulin Resistance	Dollary of ciliad	HISTORY LANGE	Insulin Resistance	Insulin Resistance	BOILESCHIED THE STATE OF THE ST	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Decision	HISTORIAL VESTSTANCE	Insulin Resistance		
Age		29	20	2		۷	٥	- (,	~	2	C	,	2	c	- «	,	۷	2	,			
Gender Age	2	Σ	Σ	2	×	ட	u		Ξ	Σ	ட	u		L.	Σ	2	Σ	ட	LL.	lu			
t oge	23134 EC	27 - 1010.4	20102 - EAB	3111808	000110	112698	5124698	3111808	000110	42698	112698	6101600		5124698	3111898	4260B	0007	112698	6101600	5124698	2001		